Skip to content

Study on screening of proprietary Chinese Medicine in convalescent Rehabilitation treatment of COVID-19 convalescent patients

A randomized, double-blind, placebo-controlled, multicenter clinical study of Jinshuibao in improving the symptoms related to pulmonary and cardiac function of COVID-19 during convalescence

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005253
Enrollment
Unknown
Registered
2021-08-31
Start date
2020-04-27
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Hubei Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. meet the new coronary virus pneumonia recovery period diagnostic criteria; 2. short breath, sweating, dry cough, chest tightness, palpitations, etc., three symptoms, or single symptom visual simulation score method (VAS) >=4; 3. the cure discharge is more than 2 weeks; 4. aged 18 ~ 70 years old; 5. sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. other reasons causted short breath, sweating, dry cough, chest tightness, palpitations and other pulmonary heart function; 2. Patients with difficult drugs due to basic diseases; 3. with severe basic diseases that affect survival, including Uncontrolled has a clinical heart, lung, kidney, digestion, blood disease, neuroplastic disease, immune disease, metabolic disease, malignant tumor, severe malnutrition, etc.; 4. allergic body, drugs involved in treatment Allergies; 5. pregnancy or lactating women; 6. mental state can not be collaborators, suffering from mental illness, no self-control, can not clearly express; 7. are participating in other clinical trials; 8. according to researchers In case of patients affecting efficacy and safety assessment of incoming complications or poor computes.

Design outcomes

Primary

MeasureTime frame
Palpitation;Chest tightness;Hyperhidrosis;Dry cough;Short breath;

Countries

China

Contacts

Public ContactDong D+86 andan

Wuhan No.7 Hospital

365540209@qq.com15972029169

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026